These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32933323)

  • 1. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
    Eletreby R; Anees M; Naguib M; Kobtan A; Helmy A; Khalaf N; Mansour S; Hassany M; El Akel W; Hashem A; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):103-110. PubMed ID: 32933323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.
    Kuo YH; Chuang TW; Hung CH; Chen CH; Wang JH; Hu TH; Lu SN; Lee CM
    J Formos Med Assoc; 2011 Jun; 110(6):363-71. PubMed ID: 21741004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
    Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
    Meissner EG; Lee YJ; Osinusi A; Sims Z; Qin J; Sturdevant D; McHutchison J; Subramanian M; Sampson M; Naggie S; Patel K; Remaley AT; Masur H; Kottilil S
    Hepatology; 2015 Mar; 61(3):790-801. PubMed ID: 25203718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    Younossi ZM; Stepanova M; Estep M; Negro F; Clark PJ; Hunt S; Song Q; Paulson M; Stamm LM; Brainard DM; Subramanian GM; McHutchison JG; Patel K
    J Hepatol; 2016 Jan; 64(1):29-36. PubMed ID: 26341824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
    Endo D; Satoh K; Shimada N; Hokari A; Aizawa Y
    World J Gastroenterol; 2017 Apr; 23(13):2355-2364. PubMed ID: 28428715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
    da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
    Immunol Res; 2020 Jun; 68(3):111-117. PubMed ID: 32537670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral Expression of
    Afzal M; Ali A; Sheikh N; Rafique S; Idrees M
    J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?
    Andrade VG; Yamashiro FDS; Oliveira CV; Kurozawa LL; Moreira A; Silva GF
    Arq Gastroenterol; 2018; 55(2):184-187. PubMed ID: 30043871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Cheng PN; Chiu YC; Chien SC; Chiu HC
    J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
    McCabe L; White IR; Chau NVV; Barnes E; Pett SL; Cooke GS; Walker AS;
    Trials; 2020 May; 21(1):413. PubMed ID: 32423467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.